[go: up one dir, main page]

AR132037A1 - PYRIDAZINYL AMINO DERIVATIVES AS ALK5 RECEPTOR INHIBITORS - Google Patents

PYRIDAZINYL AMINO DERIVATIVES AS ALK5 RECEPTOR INHIBITORS

Info

Publication number
AR132037A1
AR132037A1 ARP240100524A ARP240100524A AR132037A1 AR 132037 A1 AR132037 A1 AR 132037A1 AR P240100524 A ARP240100524 A AR P240100524A AR P240100524 A ARP240100524 A AR P240100524A AR 132037 A1 AR132037 A1 AR 132037A1
Authority
AR
Argentina
Prior art keywords
alk5
compounds
receptor inhibitors
amino derivatives
alk5 receptor
Prior art date
Application number
ARP240100524A
Other languages
Spanish (es)
Inventor
Daniela Pizzirani
Paolo Ronchi
Daniele Pala
Donatella Rescigno
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of AR132037A1 publication Critical patent/AR132037A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En términos generales, la presente invención se refiere a compuestos que inhiben el receptor tipo I del factor de crecimiento transformante b (TGF b) (ALK5) (en adelante inhibidores de ALK5), a métodos para preparar dichos compuestos, a composiciones farmacéuticas que los contienen y al uso terapéutico que se hace de ellos. Los compuestos de la invención pueden ser útiles, por ejemplo, en el tratamiento de muchas enfermedades, trastornos o afecciones que se asocian con la vía de señalización ALK5. Un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables.In general terms, the present invention relates to compounds that inhibit the transforming growth factor b (TGF b) type I receptor (ALK5) (hereinafter ALK5 inhibitors), to methods for preparing said compounds, to pharmaceutical compositions containing them and to the therapeutic use that is made of them. The compounds of the invention may be useful, for example, in the treatment of many diseases, disorders or conditions that are associated with the ALK5 signaling pathway. A compound of formula (1) or a pharmaceutically acceptable salt thereof.

ARP240100524A 2023-03-02 2024-03-01 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 RECEPTOR INHIBITORS AR132037A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23159706 2023-03-02

Publications (1)

Publication Number Publication Date
AR132037A1 true AR132037A1 (en) 2025-05-21

Family

ID=85461637

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100524A AR132037A1 (en) 2023-03-02 2024-03-01 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 RECEPTOR INHIBITORS

Country Status (7)

Country Link
EP (1) EP4673214A1 (en)
KR (1) KR20250153294A (en)
CN (1) CN121039121A (en)
AR (1) AR132037A1 (en)
AU (1) AU2024229840A1 (en)
MX (1) MX2025009709A (en)
WO (1) WO2024180206A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4182308T3 (en) 2020-07-15 2024-10-21 Chiesi Farm Spa Pyridazinylamino derivatives as ALK5 inhibitors
TW202237119A (en) * 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
US20250011299A1 (en) * 2021-09-21 2025-01-09 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors

Also Published As

Publication number Publication date
EP4673214A1 (en) 2026-01-07
MX2025009709A (en) 2025-09-02
KR20250153294A (en) 2025-10-24
WO2024180206A1 (en) 2024-09-06
AU2024229840A1 (en) 2025-10-09
CN121039121A (en) 2025-11-28

Similar Documents

Publication Publication Date Title
CL2021003012A1 (en) nlrp3 inflammasome inhibitors
BR112023001195A2 (en) COMPOUND OR RACEMATE, STEREOISOMER, TAUTOMER, ISOTOPICALLY LABELED COMPOUND, SOLVATE, POLYMORPH, PHARMACEUTICALLY ACCEPTABLE SALT OR PRODRUG COMPOUND THEREOF, COMPOUND, METHOD OF PREPARATION FOR COMPOUND OR RACEMATE, STEREOISOMER, TAUTOMER, ISOTOPICALLY LABELED COMPOUND, POLYFOLD, SALTED, SALTED ACCEPTABLE PHARMACEUTICALLY OR PRODRUG COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR TREAT A DISEASE ASSOCIATED WITH ALTERNATIVE COMPLEMENT PATHWAY ACTIVATION, AND, USE OF THE COMPOUND
CL2021000382A1 (en) Novel sulfonamidaurea compounds
AR121483A1 (en) CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND
ECSP23054131A (en) COCRYSTAL OF A CDK INHIBITOR
CO2022012884A2 (en) Fused Amino Pyrimidine Compounds
AR127050A1 (en) SPIROCYCLIC COMPOUNDS
MX2024003399A (en) PYRIDAZINYL-AMINO DERIVATIVES AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR BETA TYPE I RECEPTOR (ALK5).
CL2022001337A1 (en) Pyridopyrimidinone derivatives as ahr antagonists
MX2023000521A (en) Pyridazinyl amino derivatives as alk5 inhibitors.
DOP2025000013A (en) NLRP3 INFLAMMASOME INHIBITORS
AR124449A1 (en) SOS1 INHIBITORS AND USES THEREOF
ECSP22082217A (en) N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL)ACETAMIDE DERIVATIVES
MX2024003028A (en) 6-aza-quinoline derivatives and related uses.
CL2019003467A1 (en) 5,6-fused bicyclic compounds and compositions for the treatment of parasitic diseases.
CO2022015823A2 (en) Luminal acting n-(piperidin-4-yl)benzamide derivatives
AR132037A1 (en) PYRIDAZINYL AMINO DERIVATIVES AS ALK5 RECEPTOR INHIBITORS
CO2024015686A2 (en) Condensed bicyclic heteroaromatic compounds and their use in cancer treatment
AR131413A1 (en) PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE
AR131414A1 (en) PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE
AR131001A1 (en) PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE
UY38133A (en) NEW INHIBITORS FROM CDK8 / 19
MX2022005843A (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5.
AR132032A1 (en) PYRIDAZINYL AMINO DERIVATIVES AS ALK5 RECEPTOR INHIBITORS
AR119280A1 (en) 2,3-DIHYDROQUINAZOLINE COMPOUNDS AS NAV1.8 INHIBITORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FB Suspension of granting procedure